Zealand Pharma A/S banner

Zealand Pharma A/S
CSE:ZEAL

Watchlist Manager
Zealand Pharma A/S Logo
Zealand Pharma A/S
CSE:ZEAL
Watchlist
Price: 241.8 DKK -34.51% Market Closed
Market Cap: kr17.3B

Wall Street
Price Targets

ZEAL Price Targets Summary
Zealand Pharma A/S

Wall Street analysts forecast ZEAL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZEAL is 704.21 DKK with a low forecast of 404 DKK and a high forecast of 1 008 DKK.

Lowest
Price Target
404 DKK
67% Upside
Average
Price Target
704.21 DKK
191% Upside
Highest
Price Target
1 008 DKK
317% Upside
Zealand Pharma A/S Competitors:
Price Targets
MGIC
Magic Software Enterprises Ltd
6% Upside
IBEX
Ibex Ltd
41% Upside

Revenue
Forecast

35% / Year
Past Growth
-53% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
35% / Year
Past Growth
-53% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

For the last 14 years the compound annual growth rate for Zealand Pharma A/S's revenue is 35%. The projected CAGR for the next 3 years is -53%.

Operating Income
Forecast

61% / Year
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
61% / Year
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss

For the last 14 years the compound annual growth rate for Zealand Pharma A/S's operating income is 61%.

Net Income
Forecast

55% / Year
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-41%
Average Miss
55% / Year
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-41%
Average Miss

For the last 14 years the compound annual growth rate for Zealand Pharma A/S's net income is 55%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ZEAL's stock price target?
Price Target
704.21 DKK

According to Wall Street analysts, the average 1-year price target for ZEAL is 704.21 DKK with a low forecast of 404 DKK and a high forecast of 1 008 DKK.

What is Zealand Pharma A/S's Revenue forecast?
Projected CAGR
-53%

For the last 14 years the compound annual growth rate for Zealand Pharma A/S's revenue is 35%. The projected CAGR for the next 3 years is -53%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett